Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...
FDA approves VEPPANU (vepdegestrant), the first PROTAC therapy for ESR1 mutated metastatic breast cancer. Approval sets a new treatment class for a genetic subgroup that has had limited targeted ...
Pfizer ($PFE) appears to be speeding toward a crucial early FDA approval for palbociclib, a breast cancer treatment with blockbuster potential, pivoting from its ...
By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with ...
An infectious disease expert has dismissed calls for more COVID vaccine makers to withdraw their jabs. Here’s why.
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
AstraZeneca PLC announced a deal with President Donald Trump that’s focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfizer Inc. “Today, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results